Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

Q3 Revenue Rises Despite Pandemic’s Impacts On Vaccines Business

old chronometer
Merck& Co.'s COVID-19 programs are not the fastest in the clinic but may have oral or one-time dosing advantages

More from Earnings

More from Business